Literature DB >> 9832339

Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.

A Nordenhem1, B Wiman.   

Abstract

In many studies, tPA antigen has been a strong predictor of myocardial infarction. However, only a few percent of the total tPA antigen present in plasma samples taken at rest constitutes active tPA. The rest is enzymatically inactive and consists of a heterogeneous mixture of tPA in complex with inhibitors such as PAI-1, antiplasmin and C1 inhibitor. In the present study we developed specific two-site ELISA methods for determining the individual protease/inhibitor complexes constituting tPA antigen. We subsequently measured the concentrations of the different complexes in plasma samples taken from 30 healthy individuals. The results show that the concentration of the complex between tPA and PAI-1 in plasma correlated strongly with that of tPA antigen in plasma, as measured with a commercially available kit. Also the correlation between tPA/PAI-1 complex levels in plasma and the PAI-1 activity concentration was significant. However, no significant correlations were found between tPA antigen concentration and tPA/C1 inhibitor or tPA/antiplasmin concentrations in plasma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832339     DOI: 10.1080/00365519850186274

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

3.  Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men.

Authors:  Anne Sofie Gram; Else-Marie Bladbjerg; Jane Skov; Thorkil Ploug; Anders Sjödin; Mads Rosenkilde; Daniel Elenius Madsen; Bente Merete Stallknecht
Journal:  Eur J Appl Physiol       Date:  2015-01-25       Impact factor: 3.078

4.  Effects of inhalable particulate matter on blood coagulation.

Authors:  M Bonzini; A Tripodi; A Artoni; L Tarantini; B Marinelli; P A Bertazzi; P Apostoli; A Baccarelli
Journal:  J Thromb Haemost       Date:  2009-11-17       Impact factor: 5.824

5.  Impact of short-term antiretroviral therapy (START) on some fibrinolytic markers in HIV-infected Nigerian adults: preliminary findings from the START study.

Authors:  Zaccheaus A Jeremiah; Yetunde Obazee; Godwin R Okogun; Teddy C Adias; Osaro Mgbere; Ekere J Essien
Journal:  HIV AIDS (Auckl)       Date:  2012-07-10

6.  Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.

Authors:  M Hoshino; Y Haraguchi; H Hirasawa; M Sakai; H Saegusa; K Hayashi; N Horita; H Ohsawa
Journal:  Crit Care       Date:  2001-02-26       Impact factor: 9.097

7.  Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysis.

Authors:  Mariya Negreva; Svetoslav Georgiev; Katerina Vitlianova
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 8.  Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses.

Authors:  Peter Willeit; Alexander Thompson; Thor Aspelund; Ann Rumley; Gudny Eiriksdottir; Gordon Lowe; Vilmundur Gudnason; Emanuele Di Angelantonio
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.